We report the case of a healthy donor who was mobilized for the purpose of performing an unrelated donor transplantation with subcutaneous injections of rhG-CSF. Because of accidental loss of progenitors, 3 days after completing the first collection, the donor was mobilized again with rhG-CSF, and progenitors were collected. While a similar increase in the pre-apheresis leukocyte count was observed in both procedures, fewer mononuclear cells were mobilized during the second rhG-CSF course, resulting in a poor CD34 + yield. These data suggest that an 8-day interval between commencement of rhG-CSF mobilizations is insufficient to predict an efficient collection of hematopoietic progenitors to ensure engraftment after bone marrow transplantation. Bone Marrow Transplantation (2000) 26, 351-352. 
Transplantation of recombinant human granulocyte colonystimulating factor (rhG-CSF)-mobilized peripheral blood progenitor cells (PBPCs) is now being increasingly used for the treatment of hematological malignancies and solid tumors. A 4-5 day course of 5-10 g/kg/day rhG-CSF generally allows collection of sufficient PBPCs for transplantation (Ͼ2.0 ϫ 10 6 CD34 ϩ cells/kg) by one leukapheresis in the majority of donors. This avoids the need for general anaesthesia and marrow harvest. To date, available literature on short-term second PBPC mobilization in healthy donors is limited [1] [2] [3] and, although a reduction in PBPC yield is inversely associated with time intervals between aphereses (shortest interval described between procedures of 16 days), 3 in all cases the reduction was not severe enough to prevent effective PBPC harvesting during the second mobilization. Thus, it is unclear what is the minimum period of time required to predict an adequate number of PBPCs being mobilized and subsequently collected after repeated rhG-CSF mobilization schedules. 
Case report
A healthy 50-year-old female was mobilized for the purpose of performing an unrelated donor transplantation in another center, with subcutaneous injections of rhG-CSF, at a dosage of 10 g/kg/day. The treatment with rhG-CSF was continued for 5 consecutive days. On day 6, an apheresis was accomplished through peripheral veins using a COBE Spectra cell separator (Cobe, Lakewood, CO, USA) by processing 15 l of donor blood. Because of accidental loss of progenitors, the donor was proposed for re-mobilization. A second informed consent was obtained after detailed explanations of early and late side-effects, and of the limited experience in the literature about repetitive short-term mobilizations. Thus, 3 days after completing the first collection, the donor was mobilized again with 11.3 g/kg/day rhG-CSF for 4 consecutive days, and PBPCs were apheresed on day 5 in a similar manner. On the days of aphereses, peripheral blood and the collected product were analyzed. Total nucleated cell counts were determined on a cell counter (STKS; Coulter Electronics, Hialeah, FL, USA), and CD34 ϩ cell counts were assessed by labelling cells with the HPCA-2 CD34 antibody (Becton Dickinson, Mountain View, CA, USA) and analyzed using a FACSCalibur flow cytometer (Becton Dickinson).
The treatment with rhG-CSF was well tolerated during both mobilizations, with mild bone pain not requiring analgesics. The pre-apheresis leukocyte counts in the first and second procedures were similar, but a pronounced decrease in the concentration of mononuclear cells was observed before the second PBPC collection, compared to the first apheresis procedure (Table 1) . Accordingly, a marked Table 1 Cell counts of peripheral blood and apheresis products on day of first and second collections, with a time interval of 7-days between both procedures reduction in the CD34 cell yield was obtained in the apheresis product collected after the second mobilization compared with the first mobilization ( Table 1 ). The donor declined to undergo further collection procedures.
Mobilization

Discussion
New transplantation strategies, such as T cell-depleted PBPC transplants or double allogeneic PBPC transplants, increase the need for high CD34 ϩ yields and for repeated mobilizations. The use of rhG-CSF-mobilized PBPCs has increased tremendously over the last few years. Although the precise mechanisms of mobilization are unknown, the mobilizing stimulus contributes both to proliferation and differentiation of progenitors, and to perturbation of the interactions between marrow progenitor cells and stromal elements, thus permitting their eventual egress into the circulation from where PBPCs can be collected. 4 The timing needed for the progenitor cell compartment to reconstitute after initial rhG-CSF mobilizing regimen in healthy donors remains unknown, but previous data indicate that effective CD34 ϩ harvesting is achieved during repetitive mobilization, with intervals between collections of more than 2 weeks. [1] [2] [3] In the present case, the short interval of 1 week between collections resulted in a similar increase in the preapheresis leukocyte count, in both procedures. In spite of that fact, fewer mononuclear cells were mobilized during the second rhG-CSF course, resulting in a poor CD34 ϩ yield. Thus, contrary to previous data indicating a correlation between pre-apheresis leukocyte count and CD34 ϩ yields in single mobilization, 5 in short-term second mobilizations this parameter might not have such a good predictive value. Together, these data suggest that an 8-day interval between commencement of rhG-CSF mobilizations, permits the release of mature cells to the blood stream, but is not sufficient for reconstitution of the stem cell compartment to allow harvesting of sufficient cells to ensure hematopoietic engraftment after transplantation.
